Merck Accounts Payable 2010-2025 | MRK
Merck accounts payable from 2010 to 2025. Accounts payable can be defined as amounts payable to vendors extended as a line of credit for normal business purchases.
- Merck accounts payable for the quarter ending June 30, 2025 were $3.892B, a 10.6% increase year-over-year.
- Merck accounts payable for 2024 were $4.079B, a 4% increase from 2023.
- Merck accounts payable for 2023 were $3.922B, a 8.02% decline from 2022.
- Merck accounts payable for 2022 were $4.264B, a 7.49% decline from 2021.
Merck Annual Accounts Payable
(Millions of US $) |
| 2024 |
$4,079 |
| 2023 |
$3,922 |
| 2022 |
$4,264 |
| 2021 |
$4,609 |
| 2020 |
$4,327 |
| 2019 |
$3,738 |
| 2018 |
$3,318 |
| 2017 |
$3,102 |
| 2016 |
$2,807 |
| 2015 |
$2,533 |
| 2014 |
$2,625 |
| 2013 |
$2,274 |
| 2012 |
$1,753 |
| 2011 |
$2,023 |
| 2010 |
$2,308 |
| 2009 |
$2,244 |
Merck Quarterly Accounts Payable
(Millions of US $) |
| 2025-06-30 |
$3,892 |
| 2025-03-31 |
$3,784 |
| 2024-12-31 |
$4,079 |
| 2024-09-30 |
$3,586 |
| 2024-06-30 |
$3,519 |
| 2024-03-31 |
$3,514 |
| 2023-12-31 |
$3,922 |
| 2023-09-30 |
$3,509 |
| 2023-06-30 |
$3,442 |
| 2023-03-31 |
$3,680 |
| 2022-12-31 |
$4,264 |
| 2022-09-30 |
$3,371 |
| 2022-06-30 |
$3,482 |
| 2022-03-31 |
$3,715 |
| 2021-12-31 |
$4,609 |
| 2021-09-30 |
$3,366 |
| 2021-06-30 |
$3,897 |
| 2021-03-31 |
$4,034 |
| 2020-12-31 |
$4,327 |
| 2020-09-30 |
$3,744 |
| 2020-06-30 |
$3,448 |
| 2020-03-31 |
$3,572 |
| 2019-12-31 |
$3,738 |
| 2019-09-30 |
$3,198 |
| 2019-06-30 |
$3,142 |
| 2019-03-31 |
$3,018 |
| 2018-12-31 |
$3,318 |
| 2018-09-30 |
$3,091 |
| 2018-06-30 |
$3,024 |
| 2018-03-31 |
$3,162 |
| 2017-12-31 |
$3,102 |
| 2017-09-30 |
$2,620 |
| 2017-06-30 |
$2,934 |
| 2017-03-31 |
$2,484 |
| 2016-12-31 |
$2,807 |
| 2016-09-30 |
$2,481 |
| 2016-06-30 |
$2,514 |
| 2016-03-31 |
$2,241 |
| 2015-12-31 |
$2,533 |
| 2015-09-30 |
$2,023 |
| 2015-06-30 |
$2,335 |
| 2015-03-31 |
$2,091 |
| 2014-12-31 |
$2,625 |
| 2014-09-30 |
$2,279 |
| 2014-06-30 |
$2,326 |
| 2014-03-31 |
$2,434 |
| 2013-12-31 |
$2,274 |
| 2013-09-30 |
$2,469 |
| 2013-06-30 |
$2,253 |
| 2013-03-31 |
$2,084 |
| 2012-12-31 |
$1,753 |
| 2012-09-30 |
$1,804 |
| 2012-06-30 |
$1,674 |
| 2012-03-31 |
$2,358 |
| 2011-12-31 |
$2,023 |
| 2011-09-30 |
$2,282 |
| 2011-06-30 |
$2,143 |
| 2011-03-31 |
$2,402 |
| 2010-12-31 |
$2,308 |
| 2010-09-30 |
$2,242 |
| 2010-06-30 |
$2,172 |
| 2010-03-31 |
$2,075 |
| 2009-12-31 |
$2,244 |
| 2009-09-30 |
$568 |
| 2009-06-30 |
$527 |
| 2009-03-31 |
$623 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$210.338B |
$64.168B |
|
Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co.
|
